Skip Navigation

Cardiovascular Research 1997 35(1):158-167; doi:10.1016/S0008-6363(97)00086-2
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hutchinson, H. G
Right arrow Articles by Pratt, R. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutchinson, H. G
Right arrow Articles by Pratt, R. E
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells

Howard G Hutchinson1, Pedro T Trindade2, Dolores B Cunanan, Can-Fang Wu3 and Richard E Pratt*

Falk Cardiovascular Research Center, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA

* Corresponding author. Current address: Laboratory of Genetic Physiology, Brigham and Women's Hospital, Thorn-12, 75 Francis Street, Boston, MA 02115, USA. Tel.: +1 (617) 732-8799; fax: +1 (617) 975-0995; e-mail: rpratt@bustoff.bwh.harvard.edu

Objective: While natriuretic peptides can inhibit growth of vascular smooth muscle cells (VSMC), controversy exists as to whether this effect is mediated via the guanylate cyclase-coupled receptors, NPR-A and NPR-B, or the clearance receptor, NPR-C. The original aim of this study was to examine the mechanism by which the NPR-C receptor regulates growth. Methods: Rat VSMC were characterized with regard to natriuretic peptide receptor expression by RT/PCR and radioligand binding studies. The effect on growth following addition of the peptides and the ligands for NPR-C was measured by [3H]thymidine incorporation. Cyclic guanosine monophosphate (cGMP) levels were determined by radioimmunoassay and mitogen activating protein kinase activity was based on the phosphorylation of myelin basic protein. Results: In rat VSMC, passages 4–12, both atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) dose-dependently inhibited serum and PDGF-induced VSMC growth. In contrast, NPR-C specific ligands alone had no effect on cell growth but enhanced growth inhibition when co-administered with ANP and CNP. ANP and CNP also decreased PDGF-BB-stimulated MAP kinase activity. Once again, NPR-C specific ligands alone had no effect but enhanced the effects of ANP. Furthermore, a cGMP specific phosphodiesterase inhibitor dose-dependently inhibited VSMC growth and markedly enhanced natriuretic-peptide-induced inhibition at low peptide concentrations. To examine a potential mechanism for the controversy concerning the NPR-C, we investigated the autocrine expression of ANP and CNP by VSMC and found that mRNA encoding both peptides could be detected by RT/PCR. Conclusion: Our findings indicate that the guanylyl-cyclase-linked receptors mediate the antiproliferative actions of the natriuretic peptides on vascular smooth muscle cell growth. Moreover, we hypothesize that the apparent inhibition of growth by NPR-C specific ligands reported by others may be due to stabilization of natriuretic peptides produced by the cultured VSMC and subsequent action of these peptides at guanylyl-cyclase-linked receptors.

KEYWORDS ANP; Growth; Radioimmune assay; cGMP; MAP kinase; Receptors; Vascular smooth muscle cell proliferation; Rat, vascular smooth muscle cells


1 Current address: Cardiovascular and Licensing, Zeneca Pharmaceuticals, 1800 Concord Pike, PO Box 15437, Wilmington, DE 19850, USA.

2 Current address: Centre de Cardiologie, Hôpital Cantonal Universitaire de Genève, 24, rue Micheli-du-Crest, 1211 Geneva 4, Switzerland.

3 Current address: Cardiovascular Research Department, Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080, USA.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.